Bio News
A U.S. Food and Drug Administration (FDA) advisory panel concluded by a 7-2 vote that the benefits of Grail’s multi-cancer blood test Galleri outweigh its risks. The panel unanimously agreed that Galleri is safe, but narrowly supported its effectiveness by a 6-4 vote. Grail has submitted a premarket approval application for Galleri, and Canaccord Genuity described the decision as a strong predictor of FDA approval.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
